Head-To-Head Analysis: NeuroMetrix (NASDAQ:NURO) & Sharps Technology (NASDAQ:STSS)
NeuroMetrix (NASDAQ:NURO – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Profitability This table compares NeuroMetrix and Sharps Technology’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NeuroMetrix -151.51% -39.85% -37.08% Sharps Technology N/A -102.25% -72.97% Valuation and Earnings This table compares NeuroMetrix and Sharps Technology’s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroMetrix $5.90 million 1.38 -$6.53 million ($6.30) -0.64 Sharps Technology N/A N/A -$9.84 million N/A N/A NeuroMetrix has higher revenue and earnings than Sharps Technology. Analyst Recommendations This is a summary of current ratings for NeuroMetrix and Sharps Technology, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroMetrix 0 0 0 0 N/A Sharps Technology 0 0 0 0 N/A Volatility & Risk NeuroMetrix has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Insider & Institutional Ownership 19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 14.1% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Summary NeuroMetrix beats Sharps Technology on 6 of the 8 factors compared between the two stocks. About NeuroMetrix (Get Free Report) NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. About Sharps Technology (Get Free Report) Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
May 20, 2024 | www.defenseworld.net
1-888-653-2347 
support@leadiq.com 
